IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...
IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the ...
BOSTON – September 17, 2022 – Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral ...
Study coordinators who want to add a study should Submit a Clinical Trial. For more information or to remove a study, please email [email protected]. MyChart is a ...
BOSTON, MA—(UPDATED) Patients with severe symptomatic degenerative mitral regurgitation (MR) ineligible for surgery fare just as well when treated with the Pascal device (Edwards Lifesciences) as ...
Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.
Preliminary 2-year results from the single-arm CLASP study show that mitral valve repair using the Pascal transcatheter system is associated with high rates of survival and freedom from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results